BioSpace News Archive

LAKEWOOD, Colo., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, or “Mesa Labs”) today reported third quarter results for the three months ended December 31, 2019. Financial Results (amounts in thousands, except per share data) In comparison to the same quarter in the prior year, third quarter revenues increased 19% to $31,655, operating (loss) income decreased 356% to $(3,381) and net (loss) income decreased 640% to $(4,630) or $(1.06) per diluted sh

Progressive Care Inc. announced that its CEO, S. Parikh Mars will present at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida - on Wednesday, February 18, 2020, at 10:00 AM Eastern Standard Time..

icometrix, world leader in software solutions to extract clinically meaningful data from brain scans is proud to announce FDA 510(k) clearance for its icobrain ep solution.

NEWTOWN, Pa., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced that Dr. Steven M. Fruchtman, President and Chief Executive Officer, will present a company update at NobleCon16 - Noble Capital Markets’ Sixteenth Annual Investor Conference, February 17-18, 2020, being held in Hollywood, FL. Dr.

CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2019.

Aptorum Group Limited (Nasdaq: APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, announces positive data and development in relation to its repurposed drug candidate, SACT-1, for the treatment of neuroblastoma, a rare type of childhood cancer that develops in infants and young children.

Feb. 10, 2020 13:00 UTC FISHERS, Ind.--( BUSINESS WIRE )-- Probo Medical (“Probo”), a leading provider of medical imaging equipment, parts, repair and service, announced today the acquisitions of Elite Medical Technologies, LLC (“Elite Medical”) and Future Medical Equipment, Ltd. (“Future Medical”). Terms of the transactions were not disclosed. “Probo is tremendously excited to announce these significant acquisitions,” said Michael Asmer, CEO of Probo Medical. “Over the past

NeuroRx will update investors at the upcoming BIO CEO conference on Monday, February 10, 2020 at 10:15am . The company’s CEO, Dr. Jonathan Javitt will be presenting an overview of recent results obtained with NRX-101, the only clinical stage drug in current development for suicidal bipolar depression. NRX-101 has been granted B